Insud Pharma
Manuel Diaz Gallego currently serves as an M&A Manager at Insud Pharma, focusing on M&A and investment activities for both Insud Pharma and its shareholders since May 2023. Prior to this role, Manuel worked at EY from December 2018 to May 2023 as an Associate in Strategy and Transactions, specializing in corporate and business valuations for various purposes, including acquisitions and goodwill impairment testing. Before their tenure at EY, Manuel was a Financial Planning Analyst in the Market Access Department at AbbVie from October 2017 to December 2018 and gained early experience as a Research Trainee at Bridgewater Consulting in 2014. Educationally, Manuel holds a Master of Science in Finance from CUNEF and bachelor's degrees in Economics from Universidad de Cantabria and Vrije Universiteit Brussel.
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.